Maryam Soleimani1, Christian Kollmannsberger1, Lucia Nappi2,3. 1. BC Cancer, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada. 2. BC Cancer, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada. lucia.nappi@bccancer.bc.ca. 3. Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. lucia.nappi@bccancer.bc.ca.
Abstract
PURPOSE OF REVIEW: This review will focus on biomarkers in testicular germ cell tumors (TGCT), focusing on microRNAs with high potential clinical application to drive management of TGCT. We explore the mechanism of action of microRNAs, literature to date, and how microRNAs may be incorporated into clinical practice in the near future. RECENT FINDINGS: MicroRNAs are small non-coding RNAs found in blood which play an important role in post-transcriptional gene regulation and have been explored in TGCT for the past 15 years. More recently, results show they are promising biomarkers for diagnosis with impressive sensitivity and specificity, while also being cost-effective. MicroRNAs will likely play a critical role in areas of unmet need in GCT in the next decade, as they have many of the characteristics of an ideal biomarker. Ongoing prospective clinical trials evaluating microRNA-371 will be eagerly awaited and will help inform decision-making in real-world application.
PURPOSE OF REVIEW: This review will focus on biomarkers in testicular germ cell tumors (TGCT), focusing on microRNAs with high potential clinical application to drive management of TGCT. We explore the mechanism of action of microRNAs, literature to date, and how microRNAs may be incorporated into clinical practice in the near future. RECENT FINDINGS: MicroRNAs are small non-coding RNAs found in blood which play an important role in post-transcriptional gene regulation and have been explored in TGCT for the past 15 years. More recently, results show they are promising biomarkers for diagnosis with impressive sensitivity and specificity, while also being cost-effective. MicroRNAs will likely play a critical role in areas of unmet need in GCT in the next decade, as they have many of the characteristics of an ideal biomarker. Ongoing prospective clinical trials evaluating microRNA-371 will be eagerly awaited and will help inform decision-making in real-world application.
Authors: Hege S Haugnes; Torgeir Wethal; Nina Aass; Olav Dahl; Olbjørn Klepp; Carl W Langberg; Tom Wilsgaard; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2010-09-20 Impact factor: 44.544
Authors: Padraig Warde; Lena Specht; Alan Horwich; Tim Oliver; Tony Panzarella; Mary Gospodarowicz; Hans von der Maase Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: Peter Albers; Roswitha Siener; Sabine Kliesch; Lothar Weissbach; Susanne Krege; Christoph Sparwasser; Harald Schulze; Axel Heidenreich; Werner de Riese; Volker Loy; Erhard Bierhoff; Christian Wittekind; Rolf Fimmers; Michael Hartmann Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: A Horwich; S D Fossa; R Huddart; D P Dearnaley; S Stenning; M Aresu; J M Bliss; E Hall Journal: Br J Cancer Date: 2013-11-21 Impact factor: 7.640